Smithbridge Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Smithbridge Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,368	Closed	-$3.4M	–	125
2025 Q1	$3.4M	Buy	+5,368	New	+$3.69M	0.63%	51
2024 Q3	$6.1M	Buy	5,806 +2,503	+76%	+$2.79M	1.05%	33
2024 Q2	$3.47M	Sell	3,303 -572	-15%	-$554K	0.72%	46
2024 Q1	$3.73M	Sell	3,875 -197	-5%	-$187K	0.77%	49
2023 Q4	$3.58M	Sell	4,072 -12	-0.3%	-$9.88K	0.81%	47
2023 Q3	$3.36M	Sell	4,084 -291	-7%	-$229K	0.83%	44
2023 Q2	$3.14M	Sell	4,375 -47	-1%	-$36.2K	0.74%	49
2023 Q1	$3.63M	Buy	4,422 +146	+3%	+$110K	0.91%	42
2022 Q4	$3.08M	Buy	+4,276	New	+$3.16M	0.82%	49

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Smithbridge Asset Management's REGN Position: Q2 2025 in Review

Smithbridge Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 5,368 shares — an estimated $3.4M sold.

Smithbridge Asset Management first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $6.1M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Smithbridge Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Smithbridge Asset Management sold 5,368 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $3.4M.
Smithbridge Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
Smithbridge Asset Management's Regeneron Pharmaceuticals position peaked at $6.1M in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Smithbridge Asset Management's 13F filing for Q2 2025, filed 29 Jul 2025.